NIH PAR · NCI · R21
PAR-25-346: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
- NOFO number
- PAR-25-346
- Type
- PAR
- Activity code
- R21
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- Dec 11, 2024
- Opens
- Jan 16, 2025
- Expires
- Jan 8, 2028
PAR-25-346 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 16, 2025 | March 16, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 16, 2025 | July 16, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 16, 2025 | November 16, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 16, 2026 | March 16, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 16, 2026 | July 16, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 16, 2026 | November 16, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 16, 2027 | March 16, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 16, 2027 | July 16, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 16, 2027 | November 16, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-346
NIH RePORTER lists 18 projects funded under PAR-25-346 in FY2022–FY2026, with $7.5M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
18
Distinct projects, FY2022–FY2026
New awards
18
Type 1 (new project) award records
NIH funding
$7.5M
Award dollars under PAR-25-346, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 18 | 18 | $7.5M |
Institutions with the most funding
- University of Tx MD Anderson Can Ctr$843K · 2 projects
- Massachusetts General Hospital$838K · 2 projects
- University of Pittsburgh at Pittsburgh$788K · 2 projects
- Scintillon Institute for Photobiology$480K · 1 project
- Albert Einstein College of Medicine$442K · 1 project
- Massachusetts Eye and Ear Infirmary$437K · 1 project
- Weill Medical Coll of Cornell Univ$435K · 1 project
- Tufts University Boston$434K · 1 project
Funding institutes
- NCI$7.5M · 18
Activity codes funded
- R2118 records
Most recent new awards
- Development of spatial B cell antigen mapping to resolve TLS function in pancreatic cancer (opens NIH RePORTER)
Massachusetts General Hospital · 1R21CA318065-01 · NCI · Notice Sep 11, 2026
$416KR21
- Improved Fibrin-targeted Radiopharmaceutical for Gastric Cancer (opens NIH RePORTER)
Massachusetts General Hospital · 1R21CA309013-01A1 · NCI · Notice Sep 3, 2026
$422KR21
- Investigation of Physical Constriction on Cancer Stem Cells (opens NIH RePORTER)
Albert Einstein College of Medicine · 1R21CA309236-01A1 · NCI · Notice Jul 15, 2026
$442KR21
- Development of genetically encoded fluorescent reporters to detect a pediatric cancer biomarker in living cells (opens NIH RePORTER)
Univ of North Carolina Chapel Hill · 1R21CA305169-01A1 · NCI · Notice Jul 10, 2026
$388KR21
- Vascular Expansion Microscopy (vascExM): A New Method for High-Resolution Optical (opens NIH RePORTER)
Johns Hopkins University · 1R21CA304850-01A1 · NCI · Notice Jun 30, 2026
$400KR21
- Ultrasound-guided cancer immunotherapy with targeted nanodroplets (opens NIH RePORTER)
University of Tx MD Anderson Can Ctr · 1R21CA304638-01A1 · NCI · Notice Jun 16, 2026
$422KR21
What its predecessor PAR-22-090 funded
PAR-25-346 reissues PAR-22-090. Its funding history is the best guide to who wins under this program: 33 projects and $13.4M in FY2022–FY2026.
Projects funded
33
Distinct projects, FY2022–FY2026
New awards
33
Type 1 (new project) award records
NIH funding
$13.4M
Award dollars under PAR-22-090, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 9 | 9 | $2.4M |
| FY2024 | 17 | 11 | $4.2M |
| FY2025 | 20 | 13 | $5.7M |
| FY2026 | 5 | 0 | $1.1M |
Institutions with the most funding
- Virginia Polytechnic Inst and St Univ$792K · 2 projects
- University of Pennsylvania$791K · 2 projects
- University of Alabama at Birmingham$785K · 2 projects
- Duke University$738K · 2 projects
- Seattle Children's Hospital$506K · 1 project
- Boston Children's Hospital$455K · 1 project
- Cleveland Clinic Lerner Com-Cwru$443K · 1 project
- Yale University$431K · 1 project
Funding institutes
- NCI$11.4M · 44
- NIDCR$1.3M · 3
- NIAMS$777K · 4
Activity codes funded
- R2151 records
Most recent new awards
- A Pathomimetic Gingiva-on-a-Chip for Assessing Microbiota-Directed Anti-Inflammatory Therapeutics (opens NIH RePORTER)
Cleveland Clinic Lerner Com-Cwru · 1R21DE035249-01 · NIDCR · Notice Aug 14, 2025
$443KR21
- Dissecting the structure-function relationship of the Wnt destruction complex condensate (opens NIH RePORTER)
University of California Santa Barbara · 1R21CA301306-01 · NCI · Notice Aug 14, 2025
$402KR21
- 3D High Density Collagen I Improves Modeling of Metastatic Pancreatic Cancer (opens NIH RePORTER)
University of California, San Diego · 1R21CA306070-01 · NCI · Notice Jul 31, 2025
$410KR21
- Underlying vasculature and perivasculature direct fluid flow in and around tumors (opens NIH RePORTER)
Virginia Polytechnic Inst and St Univ · 1R21CA297765-01A1 · NCI · Notice Jul 30, 2025
$412KR21
- Biomimetic Nitric Oxide and Hydroxyapatite Duo for Advanced Direct Pulp Capping (opens NIH RePORTER)
University of Alabama at Birmingham · 1R21DE034497-01A1 · NIDCR · Notice Jul 23, 2025
$408KR21
- Enhanced treatment of breast cancer via biodegradable polymer nanoparticles (opens NIH RePORTER)
University of Pennsylvania · 1R21CA297703-01A1 · NCI · Notice Jul 16, 2025
$392KR21
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-346. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- NIDCR · National Institute of Dental and Craniofacial Research
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission - Resubmission of applications to PAR-19-149, PAR-22-090, and this NOFO. The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The combined budget for direct costs for the two-year project period may not exceed 275,000. No more than 200,000 may be requested in any single year.
- Project period
- The maximum project period is 2 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-090.
Other open NOFOs for R21
- PAR-25-321Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-070Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
- PAR-25-244Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
- PA-25-253Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-143Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-044Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.